Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: <i>Post hoc</i> analysis of a Phase III study (KAKEHASI)Yoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2023Cited by 5
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trialsYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2021Cited by 5
Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trialsYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2024Cited by 4
Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance studyHideto Kameda, Yoshiya Tanaka, Toshiya Takahashi et al.|Modern Rheumatology|2024Cited by 4
Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumabYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Clinical and Experimental Rheumatology|2021Cited by 2